Arcutis Vertex: Which Pharmaceutical Stock Is Better in 2026
In 2026, investors face a classic showdown: a rapid-growth dermatology
Compare index fund performance year by year to detect stability, volatility, and opportunities for strategic adjustments.
25,004 articlesIn 2026, investors face a classic showdown: a rapid-growth dermatology
The GLP-1 wave has traders buzzing. While Lilly and Novo Nordisk hold steady as reliable bets, smart portfolios tap i...
Starboard Value’s effort at Dynatrace tests whether the observability software maker can turn around on its own or be...
Two powerhouse ideas could propel your portfolio toward the next decade: a campus-wide AI infrastructure leader and a...
Point closes $508.6m securitization, the largest HEI-backed deal to date, as institutional buyers pile into home equi...
A bold move from Rocket Lab could shift the balance in space infrastructure. This analysis breaks down the deal, its ...
A pivotal license extension in Ghana fuels a surge in Kosmos Energy. This article breaks down what the move means for...
As TJX prepares for the (tjx) 2026 earnings call, investors should focus on sales trends, inventory discipline, and o...
As Archer Aviation moves toward broader commercial programs, investors need a clear view of 2025 earnings drivers. Th...
A SpaceX IPO could unlock funding for a bold, space-based data center vision. This deep dive explains what data cente...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A wave of battlefield tech is migrating into everyday products, creating new bets for investors as 2026 markets ride ...